Revelation Biosciences, Inc. (REVB )

Currency in USD Disclaimer
$2.86 -$0.31 (-9.65%)
Open 04/24/2025
$2.82
$3.32
$2.36
$60.8

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol REVB
  • Company Revelation Biosciences, Inc.
  • Price $2.86
  • Changes Percentage -9.65
  • Change -0.305
  • Day Low $2.82
  • Day High $3.32
  • Year High $60.8
  • Year Low $2.36
  • Market Cap $2,584,426
  • Price Avg 50 EMA (D) $3.33
  • Price Avg 200 EMA (D) $11.04
  • Exchange NASDAQ
  • Volume 126,412
  • Average Volume 160,362
  • Open $3.21
  • Previous Close $3.16
  • EPS -87.68
  • PE -0.03
  • Earnings Announcement 2025-05-08 10:59:00
  • Shares Outstanding $905,228

Company brief: REVELATION BIOSCIENCES, INC. (REVB )

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

REVB Corporation News

Income Statement